Do Kim
Stock Analyst at Piper Sandler
(1.81)
# 1,333
Out of 4,412 analysts
84
Total ratings
43.42%
Success rate
-4.26%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $41.59 | +51.48% | 13 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $5.26 | +774.52% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $397.48 | -25.53% | 11 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $65.42 | +71.20% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $23.97 | +262.95% | 4 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.66 | +764.66% | 2 | Jan 19, 2023 | |
| AFMD Affimed | Maintains: Overweight | $70 → $60 | $5.03 | +1,092.84% | 6 | Dec 12, 2022 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $1 → $2 | $1.10 | +81.82% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $6.42 | +569.78% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $23.70 | +35.02% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.76 | +485.11% | 4 | Jul 26, 2022 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $19 | $14.53 | +30.76% | 3 | Jun 23, 2022 | |
| MORF Morphic Holding | Maintains: Outperform | n/a | $28.07 | - | 1 | May 3, 2021 | |
| NUVB Nuvation Bio | Initiates: Outperform | n/a | $2.68 | - | 1 | Mar 8, 2021 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Market Perform | n/a | $143.31 | - | 10 | Jan 25, 2021 | |
| XCUR Exicure | Initiates: Outperform | n/a | $0.50 | - | 1 | Dec 18, 2020 | |
| HALO Halozyme Therapeutics | Upgrades: Outperform | n/a | $38.57 | - | 6 | Jan 9, 2020 | |
| VBIV VBI Vaccines | Maintains: Outperform | n/a | $0.57 | - | 2 | Jul 27, 2018 | |
| FATE Fate Therapeutics | Maintains: Outperform | n/a | $3.80 | - | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $41.59
Upside: +51.48%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $5.26
Upside: +774.52%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $397.48
Upside: -25.53%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $65.42
Upside: +71.20%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $23.97
Upside: +262.95%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.66
Upside: +764.66%
Affimed
Dec 12, 2022
Maintains: Overweight
Price Target: $70 → $60
Current: $5.03
Upside: +1,092.84%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $1 → $2
Current: $1.10
Upside: +81.82%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $6.42
Upside: +569.78%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $23.70
Upside: +35.02%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.76
Upside: +485.11%
Scholar Rock Holding
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $14.53
Upside: +30.76%
Morphic Holding
May 3, 2021
Maintains: Outperform
Price Target: n/a
Current: $28.07
Upside: -
Nuvation Bio
Mar 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.68
Upside: -
Alnylam Pharmaceuticals
Jan 25, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $143.31
Upside: -
Exicure
Dec 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.50
Upside: -
Halozyme Therapeutics
Jan 9, 2020
Upgrades: Outperform
Price Target: n/a
Current: $38.57
Upside: -
VBI Vaccines
Jul 27, 2018
Maintains: Outperform
Price Target: n/a
Current: $0.57
Upside: -
Fate Therapeutics
Mar 6, 2018
Maintains: Outperform
Price Target: n/a
Current: $3.80
Upside: -